Nivolumab (MDX-1106 or BMS-936558), the first PD-1 inhibitor approved for colorectal cancer (CRC), was initially evaluated as a monotherapy in CRC patients in a study reported by Brahmer et al. in 2010. Here, PDCD1 is linked to colorectal carcinoma.